Brighter tomorrow

The dedicated team at Volition have a shared goal – to save lives by revolutionizing the way disease, and especially cancer, is diagnosed throughout the world.

Watch company video
View our latest company update

Early diagnosis is key

As cancer screening programs become more and more widespread, our products can help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

X Early Diagnosis
Find out

“Cancer screening tests can also improve survival and decrease mortality by detecting cancer at an early stage when treatment is more effective”

American Cancer Society
X Large Quote

Current cancer diagnosis frequently involves expensive, unpleasant and, often, invasive testing. Using our Nu.Q technology we aim to make cancer diagnosis as accessible as cholesterol or pregnancy testing

Dr. Jake Micallef, PhD, MBACSO

For more information on Nu.Qclick here

A simple test, with a small amount of blood

Rethinking the approach to cancer

Nu.Q represents a powerful step change in rethinking the approach to cancer. It is a simple solution to the challenging problem of early cancer diagnosis.

X Coats Slider
Cam High Res White Cam High Res Min
David Vanston LR David High Res Min
Jake High Res White Jake High Res Min
Lou High Res White Lou High Res Min
Jason High Res White Jason High Res Min
Gaetan High Res White Gaetan High Res Min
Jasmine High Res White2 Jasmine High Res Copy
Mark High Res White Reduced Mark Compressed
Rod High Res White Rod High Res Min
Scott3 Webp Net Resizeimage

Our expert team

Volition was established in 2010 when our team saw a chance to bring together the long-established ELISA diagnostic technology with the cutting-edge nucleosome detection and analysis techniques.

We have grown over the years and are now a collective force of distinct individuals but our aim is the same – to save lives by revolutionizing the way cancer is diagnosed.

Cameron Reynolds MBA
President & Chief Executive Officer

Cameron is an experienced entrepreneurial executive, with expertise in biotechnology companies. He has extensive experience in the management, structuring, and strategic planning of start-up companies and has held positions including Chief Executive Officer, Chief Financial Officer, and Non-Executive Director of public and private enterprises.

Cameron was educated at the University of Western Australia receiving both a Bachelor of Commerce and an MBA.

David Vanston MBA, FCCA
Group Chief Financial Officer

David has 20 years of financial management experience. Prior to Volition and Octo Telematics, David held positions as Vice President of Excorp Medical, Inc., an early-stage company, Chief Financial Officer for GrowHow Ltd and Vice President Europe, Finance for Monster Worldwide, Inc. David managed and oversaw the accounting, finance, tax, treasury, financial planning and analysis of the business.

David is a certified chartered accountant and holds an MBA from Warwick Business School.

Jake Micallef PhD MBA
Chief Scientific Officer

Jake is an experienced scientist with expertise in research and development and in the management of early stage biotechnical companies, including the manufacturing of biotechnology products and the establishment of manufacturing operations. Jake received his BSc in Biology and Chemistry, and his PhD in Physical Chemistry from King’s College London. In addition, he received his MSc in Chemical Pathology from St Thomas’ Hospital Medical School, and his MBA from Imperial College Management School. 

Louise Day
Chief Marketing and Communications Officer

Louise brings more than 20 years of marketing, sales and leadership experience to her role at Volition. Since 2011, she has served as Director and Owner of Aculd Ltd, a strategic marketing consultancy specializing in healthcare. Formerly Louise worked in various roles at Reckitt Benckiser including some overseas posts in Paris and New York. She holds a Bachelor of Arts in Business Studies from Sheffield Hallam University.

Jason Terrell MD
Chief Medical Officer & Chief Executive Officer of Volition America, Inc.

Jason has expertise in clinical medicine and in laboratory diagnostics. He was educated at Hardin-Simmon University (Biochemistry) where he graduated Summa Cum Laude, also receiving the Holland Medal of Honor. He received his Doctor of Medicine from the University of Texas Medical School at Houston and affiliate MD Anderson Cancer Center.

Jason has a strong grounding in both medicine and more specifically in diagnostics and product commercialization.

Gaetan Michel PhD
Chief Executive Officer of Belgian Volition SPRL

Gaetan has over 10 years of experience in production management. Following the completion of his PhD in 2002, Gaetan joined AAT (Advanced Array Technology), a University of Namur spin-off company as project manager in proteomics. AAT later became EAT (Eppendorf Array Technology), part of the German Eppendorf Biotech company, where Gaetan became production manager and was involved in establishing production processes and equipment. From 2007 to 2010 he worked for KitoZyme, a global manufacturer of biopolymers of fungal origin with its core business in weight management, digestive and cardiovascular health. 

Jasmine Kway Ph.D
Chief Executive Officer, Singapore Volition

Jasmine has a proven track record in achieving positive business results by developing strategic business alliances, identifying new markets, and developing business processes. As a thought leader in technology management and commercialization, she has worked with numerous health and regulatory bodies across Asia and has successfully commercialised technologies and expanded companies into the Asian markets.

Jasmine has a Bachelor of Engineering and a Doctor of Philosophy in Oceanography from the National University of Singapore.

Mark Eccleston PhD, MBA
Business Development Director

Dr Mark Eccleston is an enthusiastic and passionate biotechnology entrepreneur with over 20 years experience in the sector. He holds a PhD in Polymer Chemistry for biomedical applications and gained an MBA (entrepreneurship) from the University of Dundee in 2008.

Mark is the Managing Director of OncoLytika Ltd. a technical consultancy company working with international private and public limited companies operating in the diagnostics and therapeutic sectors as well as academia.

Dr Eccleston is the Business Development Director at Volition, a company developing next generation blood tests for early detection of cancer. Volition’s epigenetics based immunoassay approach to rapid, affordable cancer diagnostics is intended to revolutionise cancer screening and diagnosis. Mark coordinates the commercialisation of Volition’s Research Use kit range based on this proprietary Nucleosomics® technology platform. 

Rod Rootsaert LLB
Corporate Secretary

Rod is an experienced legal and corporate secretary with over ten years’ experience in providing corporate, legal and administrative services to start-up companies. He previously served as corporate secretary for several junior mining companies in the United Kingdom. Rod received a Bachelor of Laws degree from the University of Western Australia.

Scott Powell PhD
Executive Vice President, Investor Relations & Chief Financial Officer of Volition America, Inc.

Scott has nearly 20 years of experience in the U.S. capital markets and investor relations. Scott has served as Head of Investor Relations for four public companies, including Volition, and worked for several years as an investment banker. He earned his B.S. in Business Administration from Bryant University and his MA and PhD degrees from Brown University.

Press Releases
VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update
VolitionRx Limited Executes a Contract for Clinical Trial Program in Lung Cancer